Quantcast

Latest Eisai Co. Ltd. Stories

2012-08-31 08:20:01

Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or MetronidazoleTokyo/Osaka, Aug 31, 2012 - (JCN Newswire) - Takeda Pharmaceutical Company Limited (Headquarters: Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Headquarters: Osaka, President: Paul Hudson), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka; President: Michihiro Tsuchiya), and Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito)...

2012-08-20 00:20:05

Tokyo, Aug 20, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multikinase inhibitor lenvatinib mesylate ("lenvatinib") for the treatment of thyroid cancer, the drug's prospective indication.Lenvatinib, discovered and being developed in-house, is an anti-angiogenic agent with a unique inhibitory profile against the receptor tyrosine kinase family of kinases. It is a potent...

2012-07-30 04:20:03

Tokyo, July 30, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its research and development subsidiary KAN Research Institute, Inc., currently located within the Kobe Biomedical Innovation Cluster, has received official approval from the city of Kobe to take part in a special international strategic development project being implemented within the Kansai International Strategic Innovation Zone and has therefore decided to relocate to a new research facility within the Zone in...

2012-07-19 04:20:02

Tokyo, July 19, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the first data from clinical studies with E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor discovered and being developed in-house as a treatment for Alzheimer's disease, were presented during oral sessions at the Alzheimer's Association International Conference (AAIC) 2012.Beta-amyloid (Abeta) deposition in the brain is thought to be one of causes of Alzheimer's disease, and it is...

2012-07-17 12:20:03

- Partnership Based on Open Innovation That Leverages Eisai's Natural Product Chemistry-Based Drug Discovery Platform -Tokyo, July 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a research collaboration with U.S. biopharmaceutical company Verastem, Inc. for the generation of small molecule Wnt inhibitors that target cancer stem cells. Based on this agreement, Eisai will synthesize analogs of VS-507 (salinomycin) with the aim of...

2012-07-13 08:20:01

Tokyo, July 13, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that first data from clinical studies with E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor discovered in-house, will be presented during oral sessions at the Alzheimer's Association International Conference (AAIC) 2012, taking place in Vancouver, Canada from July 14 to 19, 2012. E2609 is a BACE inhibitor currently being developed by Eisai as a next-generation oral Alzheimer's disease...

2012-04-23 20:20:12

Tokyo, Apr 23, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the German Federal Joint Committee (G-BA)(1), the supreme decision-making body for the self-governing medical system in Germany, considers the use of Halaven(R) (eribulin mesylate) to have additional benefit versus comparative treatments, defined by the G-BA for women who have already had extensive prior treatment for metastatic or locally advanced breast cancer.This assessment by the G-BA affirms the additional...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related